-
May 30, 2019
Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference
-
May 8, 2019
Aileron Therapeutics Reports First Quarter 2019 Financial Results
-
May 1, 2019
Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8
-
April 3, 2019
Aileron Therapeutics Completes $26M Private Placement
-
March 29, 2019
Aileron Therapeutics Announces Pricing of $26M Private Placement
-
March 4, 2019
Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer
-
January 16, 2019
Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers
-
December 4, 2018
Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting
-
November 27, 2018
Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
-
November 7, 2018
Aileron Therapeutics Reports Third Quarter 2018 Financial Results